I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EAHAD 2025

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Feb 15 / Roche
Moving beyond limits: Exploring evidence to support active lifestyles for people with haemophilia A
Slides presented by faculty during Roche's Symposium at EAHAD 2025 - An insightful symposium on the evidence supporting active lifestyles in individuals with haemophilia A and the importance of shared decision-making processes for creating appropriate physical activity plans and treatment strategies for patients.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 15 / Roche
WATCH: Moving beyond limits: Exploring evidence to support active lifestyles for people with haemophilia A
An insightful symposium on the evidence supporting active lifestyles in individuals with haemophilia A and the importance of shared decision-making processes for creating appropriate physical activity plans and treatment strategies for patients.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 7 / Spark
Pharmacodynamics (PD) and pharmacokinetics (PK) of dirloctocogene samoparvovec in people with severe to moderately severe hemophilia A (HA)
This analysis presents PK and PD data from the Phase 1/2 long-term follow-up trial of investigational dirloctocogene samoparvovec gene therapy for HA (NCT03003533/NCT03432520). Transgene PD was measured by FVIII activity by OSA, and PK assessed by vector shedding in PBMCs and bodily fluids.
05:30 PM
Duration 1hr Milan, Italy
Joint health and physical activity in people with haemophilia A without factor VIII inhibitors before switching to emicizumab prophylaxis: BEYOND ABR study interim analysis
Castaman G, Di Minno MND, Kruse-Jarres R, Stephensen D, Lobet S, Robson S, Brocchieri C, Jimenez-Yuste V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Milan, Italy
Health-related quality of life (HRQoL), physical activity (PA) and joint health in people with severe haemophilia A (PwSHA) and a bleeding phenotype receiving emicizumab – results from the HemiNorth 2 study
Astermark J, Ranta S, Westesson L M, Hoffman M, Quere S, Castro Sanchez A Y, Robson S, Czirok T, Lassila R, Holme P A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:30 AM
Duration 75mins Milan, Italy
Moving beyond limits: Exploring evidence to support active lifestyles for people with haemophilia A
Dr Giancarlo Castaman, Greig Blamey, Paula Loughnane

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:48 AM
Duration 8mins Hall 4
Pharmacodynamics (PD) and pharmacokinetics (PK) of dirloctocogene samoparvovec in people with severe to moderately severe hemophilia A (HA)
Lindsey George

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar